A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
NCT ID: NCT05701995
Last Updated: 2025-09-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
180 participants
INTERVENTIONAL
2023-01-31
2025-05-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
NCT06042920
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
NCT05478499
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
NCT04908189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Deucravacitinib
Deucravacitinib
Specified dose on specified days.
Placebo then Deucravacitinib
Deucravacitinib
Specified dose on specified days.
Placebo
Specified dose on specified days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Deucravacitinib
Specified dose on specified days.
Placebo
Specified dose on specified days.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
* ≥ 3% of Body Surface Area (BSA) involvement at the Screening Visit and Day 1
* Dermatology Life Quality Index (DLQI) score \> 5 at the Screening Visit and Day 1
* Moderate-to-severe plaque psoriasis as defined by static Physician Global Assessment (s-PGA) ≥ 3 at the Screening Visit and Day 1
Exclusion Criteria
* Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0006
Phoenix, Arizona, United States
Local Institution - 0034
Scottsdale, Arizona, United States
Local Institution - 0015
North Little Rock, Arkansas, United States
Local Institution - 0004
Bakersfield, California, United States
Local Institution - 0009
Sacramento, California, United States
Local Institution - 0022
San Diego, California, United States
Local Institution - 0030
Centennial, Colorado, United States
Local Institution - 0024
Washington D.C., District of Columbia, United States
Local Institution - 0027
Brandon, Florida, United States
Local Institution - 0016
Coral Gables, Florida, United States
Riverchase Dermatology
Pembroke Pines, Florida, United States
Local Institution - 0037
Atlanta, Georgia, United States
Local Institution - 0020
Snellville, Georgia, United States
Local Institution - 0007
Rolling Meadows, Illinois, United States
Local Institution - 0025
Skokie, Illinois, United States
Local Institution - 0036
Springfield, Illinois, United States
Local Institution - 0003
Baton Rouge, Louisiana, United States
Local Institution - 0018
Rockville, Maryland, United States
Local Institution - 0010
Auburn Hills, Michigan, United States
Local Institution - 0002
Waterford, Michigan, United States
Local Institution - 0017
Las Vegas, Nevada, United States
Local Institution - 0035
Reno, Nevada, United States
Local Institution - 0032
New York, New York, United States
Local Institution - 0013
New York, New York, United States
Local Institution - 0001
Rochester, New York, United States
Local Institution - 0005
Bexley, Ohio, United States
Local Institution - 0012
Mayfield Heights, Ohio, United States
Local Institution - 0019
Charleston, South Carolina, United States
Local Institution - 0029
Cypress, Texas, United States
Local Institution - 0028
Frisco, Texas, United States
Local Institution - 0008
South Jordan, Utah, United States
Local Institution - 0033
Springville, Utah, United States
Local Institution - 0021
Bellevue, Washington, United States
Local Institution - 0031
Mill Creek, Washington, United States
Local Institution - 0014
Spokane, Washington, United States
Local Institution - 0040
Caguas, , Puerto Rico
Local Institution - 0038
Carolina, , Puerto Rico
Local Institution - 0039
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1276-5158
Identifier Type: REGISTRY
Identifier Source: secondary_id
IM011-237
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.